Matrixyl
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Matrixyl is the flagship matrikine — a peptide fragment the skin reads as “collagen is breaking down, make more” — and one of the most widely formulated cosmetic peptides in the world, marketed in variants like Matrixyl 3000 and Matrixyl Synthe’6. It’s the anchor of the matrikine family alongside Syn-Coll, Rigin, Tripeptide-29, and Palmitoyl Dipeptide-6.
What does it do in my body?
Matrixyl is a matrikine that mimics collagen-breakdown fragments, signaling fibroblasts to increase synthesis of collagen I, III, IV, fibronectin, and hyaluronic acid — the “build the skin back up” mechanism, as opposed to the muscle-relaxant mechanism of the neuro-relaxer family.
How can it help me?
- Where the science stands: Moderate: 7 studies, 1 human — but the human study is off-target (radiation skin toxicity, not wrinkle efficacy); OHM’s 0035 grading cites formulator wrinkle RCTs not on the public profile
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
The one on-profile human study (Röper et al., 2004) found no advantage over a comparison lotion in radiation-toxicity skin, with no notable adverse-effect signal reported. No dedicated adverse-effect data for cosmetic wrinkle-use was captured. Family-wide read: topical delivery carries a benign safety record.
Regulatory status: Cosmetic-grade OTC topical ingredient — not an FDA-reviewed drug.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Topical-only. Typical cosmetic use: ~3–8% of the trade solution in leave-on products.
What should I avoid combining — and what's synergistic?
Matrixyl doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
The flagship matrikine and one of the most-formulated cosmetic peptides in the world — mechanism well characterized in vitro, but the one public human RCT on record is off-target (a radiation-toxicity study, not a wrinkle trial), and the strongest wrinkle data appears to be industry-held.
| Class | Matrikine / collagen-signaling peptide — topical cosmetic peptide |
| Mechanism (one line) | Mimics collagen-breakdown fragments → signals fibroblasts to increase synthesis of collagen I/III/IV, fibronectin, and hyaluronic acid |
| Evidence base | Moderate: 7 studies, 1 human — but the human study is off-target (radiation skin toxicity, not wrinkle efficacy); OHM’s 0035 grading cites formulator wrinkle RCTs not on the public profile |
| Safety record | Topical-only; benign safety record (Safety: green) |
| Regulatory status | Cosmetic-grade OTC skincare ingredient, not an FDA-reviewed drug |
What it is
Matrixyl is the flagship matrikine — a peptide fragment the skin reads as “collagen is breaking down, make more” — and one of the most widely formulated cosmetic peptides in the world, marketed in variants like Matrixyl 3000 and Matrixyl Synthe’6. It’s the anchor of the matrikine family alongside Syn-Coll, Rigin, Tripeptide-29, and Palmitoyl Dipeptide-6.
How it works
Matrixyl is a matrikine that mimics collagen-breakdown fragments, signaling fibroblasts to increase synthesis of collagen I, III, IV, fibronectin, and hyaluronic acid — the “build the skin back up” mechanism, as opposed to the muscle-relaxant mechanism of the neuro-relaxer family.
What the research shows
Public profile grade: Moderate — 7 studies, 1 human.
Important honesty note on the one human study: the single human RCT on the profile (Röper et al., 2004, Strahlenther Onkol, n=20, PMID 15127162) tested a Matrixyl-containing cream for radiation skin toxicity in breast-cancer patients and found no advantage over a comparison lotion — it is not a wrinkle-efficacy trial. The supporting collagen-stimulation data is (e.g. C16-KTTKS on fibroblasts, Jones et al., 2013, PMID 23320752).
OHM’s internal 0035 categorization pass grades Matrixyl Tier C / green / recommend-eligible, citing formulator wrinkle RCTs — “Robinson 2005, Trookman 2009” — that are not on the public peptidelist profile.
Honest status: the best-known matrikine; mechanism well characterized in vitro; the strongest wrinkle data is industry-held, and the one public human RCT is off-target.
Real-world protocol
Topical-only. Typical cosmetic use: ~3–8% of the trade solution in leave-on products.
Side effects & management
The one on-profile human study (Röper et al., 2004) found no advantage over a comparison lotion in radiation-toxicity skin, with no notable adverse-effect signal reported. No dedicated adverse-effect data for cosmetic wrinkle-use was captured. Family-wide read: topical delivery carries a benign safety record.
Regulatory status
Cosmetic-grade OTC topical ingredient — not an FDA-reviewed drug.
Sources
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Moderate, 7 studies, 1 human. Studies cited: Röper et al., 2004, Strahlenther Onkol, PMID 15127162; Jones et al., 2013, PMID 23320752.
- OHM tier/safety grading: Tier C / green / recommend-eligible, citing formulator RCTs “Robinson 2005, Trookman 2009”.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Syn-Coll · Rigin · Tripeptide-29 · Palmitoyl Dipeptide-6 · GHK-Cu
Sources & references
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Moderate, 7 studies, 1 human. Studies cited: Röper et al., 2004, Strahlenther Onkol, PMID 15127162; Jones et al., 2013, PMID 23320752.
- OHM tier/safety grading: Tier C / green / recommend-eligible, citing formulator RCTs “Robinson 2005, Trookman 2009”.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Syn-Coll · Rigin · Tripeptide-29 · Palmitoyl Dipeptide-6 · GHK-Cu